title: Nanotechnology for breast cancer therapy.
abstract: Breast cancer is the field of medicine with the greatest presence of nanotechnological therapeutic agents in the clinic. A pegylated form of liposomally encapsulated doxorubicin is routinely used for treatment against metastatic cancer, and albumin nanoparticulate chaperones of paclitaxel were approved for locally recurrent and metastatic disease in 2005. These drugs have yielded substantial clinical benefit, and are steadily gathering greater beneficial impact. Clinical trials currently employing these drugs in combination with chemo and biological therapeutics exceed 150 worldwide. Despite these advancements, breast cancer morbidity and mortality is unacceptably high. Nanotechnology offers potential solutions to the historical challenge that has rendered breast cancer so difficult to contain and eradicate: the extreme biological diversity of the disease presentation in the patient population and in the evolutionary changes of any individual disease, the multiple pathways that drive disease progression, the onset of 'resistance' to established therapeutic cocktails, and the gravity of the side effects to treatment, which result from generally very poor distribution of the injected therapeutic agents in the body. A fundamental requirement for success in the development of new therapeutic strategies is that breast cancer specialists-in the clinic, the pharmaceutical and the basic biological laboratory-and nanotechnologists-engineers, physicists, chemists and mathematicians-optimize their ability to work in close collaboration. This further requires a mutual openness across cultural and language barriers, academic reward systems, and many other 'environmental' divides. This paper is respectfully submitted to the community to help foster the mutual interactions of the breast cancer world with micro- and nano-technology, and in particular to encourage the latter community to direct ever increasing attention to breast cancer, where an extraordinary beneficial impact may result. The paper initiates with an introductory overview of breast cancer, its current treatment modalities, and the current role of nanotechnology in the clinic. Our perspectives are then presented on what the greatest opportunities for nanotechnology are; this follows from an analysis of the role of biological barriers that adversely determine the biological distribution of intravascularly injected therapeutic agents. Different generations of nanotechnology tools for drug delivery are reviewed, and our current strategy for addressing the sequential bio-barriers is also presented, and is accompanied by an encouragement to the community to develop even more effective ones.
authors.affiliation: Brown Institute of Molecular Medicine, Department of Biomedical Engineering, University of Texas Houston Health Science Center, 1825 Herman Pressler Street, Suite 537D, Houston, TX, 77030, USA.
authors.forename: Takemi
authors.initials: T
authors.lastname: Tanaka
authors.forename: Paolo
authors.initials: P
authors.lastname: Decuzzi
authors.forename: Massimo
authors.initials: M
authors.lastname: Cristofanilli
authors.forename: Jason H
authors.initials: JH
authors.lastname: Sakamoto
authors.forename: Ennio
authors.initials: E
authors.lastname: Tasciotti
authors.forename: Fredika M
authors.initials: FM
authors.lastname: Robertson
authors.forename: Mauro
authors.initials: M
authors.lastname: Ferrari
mesh_terms: D001943:Breast Neoplasms / Q000628:therapy*; D005260:Female; D006801:Humans; D036103:Nanotechnology / Q000379:methods*